3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lung Neoplasms
3
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Sarcoma
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Metastatic Solid Tumors
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Anus Neoplasms
1
Interventions
Doxorubicin
27
pembrolizumab
24
Radiotherapy
20
Cyclophosphamide
18
Magnetic Resonance Spectroscopy
17
Specimen Handling
14
Nivolumab
14
Ifosfamide
13
Gemcitabine
13
Surgical Procedures, Operative
11
Biopsy
11
Radiation
10
Temozolomide
9
X-Rays
8
Ipilimumab
8
pazopanib
7
fludarabine
7
cabozantinib
7
Irinotecan
7
Blood Specimen Collection
7
tazemetostat
6
liposomal doxorubicin
6
Trabectedin
6
Surveys and Questionnaires
6
Phantoms, Imaging
6
olaparib
5
eribulin
5
atezolizumab
5
anlotinib
5
Vincristine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
bintrafusp alfa protein, human
×
1 year
×
Clear all
NCT04874311
2025-08-13
TRUST
Institut Bergonié
Phase 2
Recruiting
80 enrolled